We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-20.85%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$711M
AUM Growth
-$285M
Cap. Flow
-$66.8M
Cap. Flow %
-9.4%
Top 10 Hldgs %
83.62%
Holding
33
New
5
Increased
15
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$17.6M
2
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$16.6M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.2M
4
INSY
Insys Therapeutics, Inc.
INSY
+$10M
5
ABBV icon
AbbVie
ABBV
+$9.57M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$67.4M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$28.8M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$22.3M
4
CLDX icon
Celldex Therapeutics
CLDX
+$19M
5
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 84.53%
2 Technology 0.52%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVFM
26
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$987K 0.14%
+1,359
New +$1.46M
AXGN icon
27
Axogen
AXGN
$2.27B
$925K 0.13%
+224,400
New +$899K
CTIC
28
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$672K 0.09%
+46,000
New +$795K
SIEN
29
DELISTED
Sientra, Inc.
SIEN
$606K 0.09%
5,966
-7,248
-55% -$1.64M
CLDX icon
30
Celldex Therapeutics
CLDX
$2.99B
– –
-50,117
Closed -$19M
EHTH icon
31
eHealth
EHTH
$42.2M
– –
-5,242
Closed -$67K
UTHR icon
32
United Therapeutics
UTHR
$25.8B
– –
-387,186
Closed -$67.4M
TVTY
33
DELISTED
Tivity Health, Inc. Common Stock
TVTY
– –
-1,010,025
Closed -$12.1M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Consonance Capital Management held 33 positions worth $711M, down 29% from $995M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Consonance Capital Management withdrew a net $66.8M in Q3 2015, closing 4 positions and reducing 7 holdings. Its most notable exit was United Therapeutics, an estimated $67.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Technology and Financials.

Against the trend, Consonance Capital Management opened a new position in Vanda Pharmaceuticals worth $16.2M.

  • Consonance Capital Management's largest Q3 2015 buy was Vanda Pharmaceuticals: 1,436,796 shares worth $16.2M.
  • Consonance Capital Management added most to Osiris Therapeutics, Inc. Common Stock in Q3 2015, an estimated $16.6M increase.
  • Consonance Capital Management's biggest Q3 2015 reduction was Enanta Pharmaceuticals, cutting an estimated $28.8M.
  • Consonance Capital Management fully exited United Therapeutics in Q3 2015, selling an estimated $67.4M.
  • Consonance Capital Management's ten largest holdings make up 84% of its $711M portfolio in Q3 2015.
  • Consonance Capital Management opened 5 new positions and closed 4 in Q3 2015.
  • Consonance Capital Management's portfolio value fell 29% quarter-over-quarter to $711M.

Based on Consonance Capital Management's 13F filing for Q3 2015, filed 9 Nov 2015.